Isofol appoints nomination committee ahead of the Annual General Meeting 2022

GOTHENBURG, Sweden, November 19, 2021 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2022 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting on 23 June 2021.

According to the instructions for appointment of the nomination committee for Isofol Medical AB (publ), the nomination committee shall consist of four members, of which one member shall consist of the chairman of the board. The other three members consist of representatives appointed by the three largest shareholders in the company in terms of the number of votes based on the share register or other reliable information provided by Euroclear Sweden AB as of September 30, 2021. Another nomination committee member may be appointed by minority shareholders representing at least 10 percent of the votes. The chairman of the nomination committee shall consist of the largest shareholder in terms of votes at the time of the nomination committee’s appearance, unless the nomination committee agrees otherwise, and may not consist of the chairman of the board or another board member.

The nomination committee has had its first meeting where the composition of the nomination committee has been determined.

The nomination committee ahead of the AGM 2022 consists of the following members:

  • Malin Björkmo, chairman of the nomination committee, appointed by Handelsbanken Fonder representing approximately 3.68 percent of the shares and votes,
  • Lars Lind, appointed by Hans Enocson representing approximately 2.82 percent of the shares and votes,
  • Ulrik Grönvall, appointed by Swedbank Robur Fonder which represents about 2.59 percent of the shares and votes, and
  • Pär-Ola Mannefred, chairman of the board of Isofol Medical AB (publ)

In addition, representatives of minority owners who represent approximately 12.51 percent of votes and shares have appointed Matsola Palm.

The members of the nomination committee are appointed by owners who represent a total of about 21.60 percent of the total number of shares and votes in Isofol Medical AB (publ) according to the ownership conditions as of September 30, 2021.

Information about the nomination committee’s work and the instructions to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summon to the annual general meeting 2022 and on the company’s website, www.isofolmedical.com.

Shareholders who wish to submit proposals to the nomination committee shall do this in writing by sending an e-mail to valberedningen@isofolmedical.com (heading: “Isofol’s nomination committee”) or by mail to the following address:

Isofol Medical AB (publ)
Att. Valberedningen
Arvid Wallgrens Backe 20
413 46 GOTHENBURG
SWEDEN

Any proposals must be received by the nomination committee no later than March 28, 2022 to be included in the notice and agenda for the Annual General Meeting 2022.

For more information, please contact

Pär-Ola Mannefred, chairman of the board
E-mail: par-ola.mannefred@residenset.se

Isofol Medical AB (publ)
Ulf Jungnelius, M.D., CEO
E-mail: jungnelius@isofolmedical.com
Telephone: +46 709-16 89 55

The information was submitted for publication, through the agency of the contact person set out above, at 13:10 CET, on November 19, 2021.

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global pivotal Phase III study, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit more patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is listed on Nasdaq Stockholm.

www.isofolmedical.com

Document